NASDAQ · GERN
Geron Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GERN: Nov 04, 2026
Geron Corporation Common Stock is expected to report earnings on 11/04/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.01. The reported EPS for the same quarter last year was $-0.03.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.01 | $0.00 | $-0.02 | 4 |
| Dec 2026 | $0.00 | $0.00 | $-0.01 | 4 |
| Mar 2027 | $0.01 | $0.01 | $0.01 | 1 |
| Jun 2027 | $0.03 | $0.03 | $0.03 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks · MarketBeat- RTTNews · Oct 30, 12:56 PM EDTWeekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals(RTTNews) – The biotech sector stayed active this week, with a mix of regulatory approvals, strategic partnerships, M&A activity, and clinical trial developments.
- Fintel · Oct 29, 2:28 AM EDTGeron Corporation Discontinues Phase 3 IMpactMF Trial of Imetelstat in Relapsed/Refractory MyelofibrosisGeron Corporation announced on October 28, 2026, its decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. The decision followed a recommendation from the independent Data Monitoring Committee, which advised t
- RTTNews · Oct 28, 9:01 AM EDTGeron Discontinues Phase 3 IMpactMF Trial Of Imetelstat In Myelofibrosis; Data Analysis Planned(RTTNews) – Geron Corporation (GERN) announced plans to discontinue its Phase 3 IMpactMF clinical trial evaluating imetelstat in patients with relapsed or refractory myelofibrosis following a recommendation from the independent Data Monitoring Committee (DMC).
- Zacks · Oct 7, 1:30 PM EDTCan Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.
- MarketBeat · Sep 16, 9:02 AM EDTGeron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption ExpandsGeron Corporation: FDA Approval Fuels Stock Price SurgeGeron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward
- MarketBeat · Sep 13, 10:01 AM EDTGeron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use ExpandsGeron Corporation: FDA Approval Fuels Stock Price SurgeGeron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the
- RTTNews · Aug 20, 5:04 PM EDTActive Biotech's Q2 Loss Shrinks As Dosing Begins In Myelofibrosis Trial(RTTNews) – Active Biotech AB (publ) (ACTI.ST), an immunomodulatory treatment company, on Thursday announced interim financial results for the second quarter and registered a marginally lower loss as clinical trials ensued only prior to and after the period.
- RTTNews · Aug 6, 7:47 AM EDTGeron Q2 2026: RYTELO Growth Support Guidance(RTTNews) – Geron Corporation (GERN) on Wednesday reported second quarter 2026 results with revenue growth from RYTELO but modestly wider net loss. Guidance for the year signals continued expansion.
- The Motley Fool · Aug 6, 12:28 AM EDTGeron (GERN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 5, 11:38 PM EDTTop Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High(RTTNews) – Today's top biotech gainers include Attovia Therapeutics, which surged following its Nasdaq debut; American Well, after reporting a narrower loss; Perrigo, which swung back to profit; and UroGen Pharma, following strong second-quarter financial results, among others.
- MarketBeat · Aug 5, 9:04 AM EDTGeron Q2 Earnings Call HighlightsGeron Corporation: FDA Approval Fuels Stock Price SurgeGeron (NASDAQ:GERN) reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic syndro
- Zacks · Aug 5, 9:00 AM EDTGeron (GERN) Reports Q2 Loss, Beats Revenue EstimatesGeron (GERN) delivered earnings and revenue surprises of -100.00% and +4.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Geron Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.